Alnylam Pharmaceuticals 주식 (NASDAQ: ALNY)

에 대한 최신 뉴스 Alnylam Pharmaceuticals (NASDAQ:ALNY) 주식

ALNYLAM PHARMACEUTICALS INC

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

The Robinhood Trade

Equities

Large Cap

News

Movers

Trading Ideas

ALNY

DUOL

ESLT

HOOD

MUFG

ROKU

SHOP

지난주에 가장 성과가 좋았던 대형주 10종목은 다음과 같다. 앨나일람, 로쿠, 로빈후드, 엘빗, 보잉, 앵글로골드, 쇼피파이, 사우스웨스트항공, 미쓰비시 파이낸셜, 듀오링고

로빈후드·로쿠·쇼피파이 등 지난주 급등한 대형주 (3월 17일~21일)

Coinbase Photo by rafapress on Shutterstock

COIN

MBLY

MRNA

RIVN

SMMT

STLA

FLSR

이들 11개 대형주들은 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?1. 휴마나(NYSE:HUM)가 별 등급의 2025년 실적 하락과 이것이 2026년 품질 보너스 지급에 어떤 영향을 미칠지에 대해 투자자들에게 업데이트한 후 주가는 24.89% 하락했다. 몇몇 분석가들은 주가 예측을 낮췄다.

코인베이스, 나이키 및 모더나는 지난주 최악의 성과를 보인 11개 대형주 중 일부 (9월 30일-10월 4일)

DoorDash

CHRW

COKE

CVNA

DASH

DXCM

EXAS

Laboratory Corporation Of America Holdings

PYPL

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 이그젝트 사이언스(NASDAQ:EXAS)가 예상보다 나은 2분기 재무 결과를 보고하고 트윈스트랜드 바이오사이언스(TwinStrand Biosciences)와 독점 라이센스 계약을 발표한 후 주가는 26.60% 상승했다. 몇몇 분석가들은 주식에 대한 가격 예측을 하향 조정했다.

도어대시와 이그젝트 사이언스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (7월 28일-8월 3일)

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $500 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $500 Price Target

Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over the last quarter vary from bullish to bearish, as provided by 27 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">15</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $338.44, with a high estimate of $500.00 and a low estimate of $280.00. Witnessing a positive shift, the current average has risen by 5.09% from the previous average price target of $322.04.
<img src="https://www.benzinga.com/files/images/story/2025/1743458484_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$342.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Joshua Smith</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$353.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$351.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$338.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$287.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$384.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$300.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$284.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$314.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Alnylam Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>About Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Alnylam Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 34.9%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -14.12%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -168.47%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.98%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 19.32. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know

Scotiabank analyst Greg Harrison maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Sector Outperform and raises the price target from $338 to $342.

Scotiabank Maintains Sector Outperform on Alnylam Pharmaceuticals, Raises Price Target to $342

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 10.98% on an annualized basis producing an average annual return of 18.93%. Currently, Alnylam Pharmaceuticals has a market capitalization of $34.33 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,328.04 today based on a price of $265.25 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743433215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Redburn Atlantic analyst Joshua Smith initiates coverage on Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy rating and announces Price Target of $353.

Initiation

Redburn Atlantic Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces Price Target of $353

The U.S. Food and Drug Administration on Friday approved Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with hemophilia A or B with or without <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">factor VIII or IX inhibitors</a>.
The <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-03-28-20-07-38-3051637" rel="noreferrer noopener">approval</a> is based on data from the ATLAS phase 3 studies that demonstrated clinically meaningful bleed protection as measured by annualized bleeding rates (ABR).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44418639/sanofi-strengthens-its-immune-system-focused-pipeline-with-around-2-billion-dren-bio-deal" rel="noreferrer noopener">Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal</a>
By lowering AT, a protein that inhibits blood clotting, Qfitlia helps increase thrombin generation to restore hemostasis in hemophilia patients.
In the ATLAS clinical development program, Qfitlia demonstrated low bleed rates across subgroups with as few as six injections a year. Key results include:
<ul>
<li>Significant bleed reduction by 71% in ABR for patients without inhibitors treated with Qfitlia prophylaxis compared to clotting factor concentrate on-demand and by 73% in ABR compared to bypassing agent on-demand for patients with inhibitors (estimated mean: ABR 5.1 vs. 19.1, respectively).</li>
<li>Median observed ABR during the open-label extension study was 3.8 in patients without inhibitors and 1.9 in patients with inhibitors.</li>
<li>The median annualized spontaneous bleeding rate observed during the open-label extension study was 1.9 in patients without inhibitors and 1.9 in patients with inhibitors.</li>
<li>Nearly half of the patients in the open-label extension study experienced one or fewer bleeds (31% zero bleeds and 47% 0-1 bleeds).</li>
</ul>
With the Qfitlia approval, the FDA cleared the Siemens Healthineers' INNOVANCE&nbsp;Antithrombin assay as a companion diagnostic for Qfitlia to measure AT levels.
Qfitlia is a small interference RNA therapeutic that utilizes Alnylam Pharmaceutical Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) ESC-GalNAc conjugate technology.
Through the Qfitlia Testing Program with Labcorp, the FDA-cleared companion diagnostic will be available to patients prescribed Qfitlia to measure AT levels at no cost.
A regulatory submission for Qfitlia for hemophilia A or B in adults and adolescents with or without inhibitors is under review in Brazil. A regulatory decision is expected in China in the second half of 2025.
Price Action: SNY stock is down 1.74% at $54.85 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44544761/european-drug-regulator-gives-thumbs-down-to-eli-lillys-alzheimers-drug-analyst-says-it-is-incremental-win-for-biogen" target="_blank" rel="noreferrer noopener">European Drug Regulator Gives Thumbs Down To Eli Lilly&#8217;s Alzheimer&#8217;s Drug, Analyst Says It Is Incremental Win For Biogen</a></li>
</ul>
Image by HJBC via Shutterstock.

Biotech

Health Care

General

FDA Approves Sanofi's Hemophilia Drug

Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $300 to $345.

Stifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $345

<ul>
<li>− New Data Follow Recent U.S. FDA Approval of AMVUTTRA&#xAE; (vutrisiran) as First RNAi Therapeutic to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Patients with ATTR-CM –</li>
<li>− Vutrisiran Favorably Impacted Echocardiographic Systolic and Diastolic Function –</li>
<li>− Vutrisiran Treatment Led to Maintenance or Improvement in Functional Capacity, Health Status, and Quality of Life, Compared to Placebo –</li>
<li>− Benefits of Vutrisiran Observed Across Baseline Heart Failure Severities, with Greatest Benefit in Patients with Early Disease –</li>
</ul>

Reported Saturday, Alnylam Presents HELIOS-B Data Highlighting Vutrisiran's Multidimensional Benefits In ATTR-CM At Annual Scientific Session 2025

Sanofi Says With Qfitlia Approval, FDA Also Cleared Siemens Healthineers' Innovance Antithrombin Assay As Companion Diagnostic For Qfitlia

The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) supplemental application for Amvuttra (vutrisiran).
The drug treats adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM, to reduce cardiovascular mortality, cardiovascular hospitalizations, and <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">urgent heart failure visits</a>.
ATTR-CM is a rare heart condition where a protein called transthyretin (TTR) misfolds and deposits in the heart, causing it to stiffen and potentially leading to heart failure.&nbsp;
The approval expands the indication for Amvuttra, which now becomes the first and only therapeutic approved by the FDA for ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44436749/alnylams-amvuttra-secures-fda-approval-for-expanded-use-for-rare-heart-disease-stock-jumps" rel="noreferrer noopener">amyloidosis (hATTR-PN) in adults.</a>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42793098/denali-therapeutics-poised-for-growth-analyst-optimistic-around-neurodegenerative-disease-platform" rel="noreferrer noopener">Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic</a>
JPMorgan upgraded Alnylam on Monday, citing a convincing multi-billion dollar opportunity for Amvuttra in TTR amyloidosis.
Following the survey, the analyst models a larger ATTR-CM market and higher overall sales for Amvuttra over time.
Analyst Jessica Fye models Amvuttra sales in cardiomyopathy (CM) of around $81 million in 2025 (vs. around $79 million prior), weighted towards 2H.
JP Morgan has upgraded to an Overweight rating from Neutral, raising the <a target="_blank" href="https://www.benzinga.com/quote/ALNY/analyst-ratings" rel="noreferrer noopener">price target from $280 to $328</a>.
&#8220;We see a majority of this opportunity from the large and growing ATTR-CM market where we expect strong uptake for Amvuttra in newly diagnosed patients but also from patients progressing on prior lines of therapy. This, in addition to ALNY's broad and attractive platform and intriguing pipeline supports what we see as a strong outlook for the business and our Overweight rating,&#8221; JP Morgan writes.
Price Action: ALNY stock is up 3.50% at $293.25 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44460532/unity-biotechnology-unveils-mixed-data-from-study-for-diabetes-related-blindness-stock-falls" target="_blank" rel="noreferrer noopener">Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls</a></li>
</ul>

Analyst Color

Upgrades

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

WIIM

Alnylam Pharmaceuticals shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised the price target from $280 to $328.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Chardan Capital slashed Century Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) price target from $11 to $7. Chardan Capital analyst Geulah Livshits maintained a Buy rating. Century Therapeutics shares closed at $0.5550 on Friday. <a href="https://www.benzinga.com/quote/IPSC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) from $296 to $269. Piper Sandler analyst Peter Keith maintained an Overweight rating. Lowe&#8217;s shares closed at $227.07 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">view this stock</a>.</li>
<li>JP Morgan boosted Alnylam Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $280 to $328. JP Morgan analyst Jessica Fye upgraded the stock from Neutral to Overweight. Alnylam Pharmaceuticals shares closed at $283.34 on Friday. <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut the price target for FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from $300 to $275. Jefferies analyst Stephanie Moore upgraded the stock from Hold to Buy. FedEx shares closed at $230.33 on Friday. <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barrington Research lowered the price target for Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) from $70 to $54. Barrington Research analyst Vincent Colicchio maintained an Outperform rating. Concentrix shares closed at $44.93 on Friday. <a href="https://www.benzinga.com/quote/CNXC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group cut RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) price target from $500 to $420. Telsey Advisory Group analyst Cristina Fernandez maintained an Outperform rating. RH shares settled at $242.18 on Friday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group cut Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) price target from $159 to $131. Evercore ISI Group analyst Stephen Kim downgraded the stock from Outperform to In-Line. Lennar shares closed at $115.22 on Friday. <a href="https://www.benzinga.com/quote/LEN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim raised Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) price target from $39 to $40. Guggenheim analyst Michael Morris upgraded the stock from Neutral to Buy. Pinterest shares closed at $32.42 on Friday.  <a href="https://www.benzinga.com/quote/PINS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James cut the price target for Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) from $96 to $82. Raymond James analyst Simon Leopold upgraded the stock from Outperform to Strong Buy. Lumentum shares settled at $66.61 on Friday. <a href="https://www.benzinga.com/quote/LITE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) price target from $30 to $31. Stifel analyst Steven Wieczynski maintained a Buy rating. Carnival shares closed at $20.94 on Friday. <a href="https://www.benzinga.com/quote/CCL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44454777/top-3-risk-off-stocks-that-may-explode-this-month-2">Top 3 Risk Off Stocks That May Explode This Month</a></li>
</ul>

Pre-Market Outlook

CNXC

IPSC

LITE

PINS

Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday

JP Morgan analyst Jessica Fye upgrades Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) from Neutral to Overweight and raises the price target from $280 to $328.

JP Morgan Upgrades Alnylam Pharmaceuticals to Overweight, Raises Price Target to $328

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) shares upped 17.20% after the company secured FDA approval of sNDA for its RNAi therapeutic, AMVUTTRA, <a href="https://www.benzinga.com//node/44436749" target="_blank" rel="noreferrer noopener">for the treatment of ATTR-CM in adults</a>.</li>
<li>Roku Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) stock surged 15.51% after the announcement that Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) launched its Truth+ <a href="https://www.benzinga.com//node/44405898" target="_blank" rel="noreferrer noopener">streaming app on the Roku platform</a>.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) stock upped 13.05% after Compass Point initiated coverage with a Buy rating and<a href="https://www.benzinga.com/quote/hood/analyst-ratings" target="_blank" rel="noreferrer noopener"> announced a price forecast of $61</a>.</li>
<li>Elbit Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) shares increased 11.72% after the company reported better-than-expected fourth-quarter 2024 results and raised the <a href="https://www.benzinga.com//node/44376371" target="_blank" rel="noreferrer noopener">quarterly dividend to $0.60/share</a>.</li>
<li>Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares grew 10.07% after President Trump awarded the company a next-generation fighter jet contract.</li>
<li>AngloGold Ashanti PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) shares upped 10.05%, probably due to strength in gold and silver. Gold reached an all-time high.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) shares were up 9.87%, driven by overall market strength following the Federal Reserve's <a href="https://www.benzinga.com//node/44406912" target="_blank" rel="noreferrer noopener">decision to hold interest rates steady</a>.</li>
<li>Southwest Airlines Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) stock was up 9.77%. Several analysts <a href="https://www.benzinga.com//node/44417227" target="_blank" rel="noreferrer noopener">raised the price forecast</a>.</li>
<li>Mitsubishi UFJ Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>) stock rose 9.66%, probably due to sympathy with the overall market sentiment after the Fed policy decision to keep rates unchanged.</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) stock gained 9.09% last week. Citizens Capital Markets <a href="https://www.benzinga.com/quote/DUOL/analyst-ratings" target="_blank" rel="noreferrer noopener">upgraded the stock</a> to Market Outperform with a $400 price forecast.</li>
</ol>
Image via Shutterstock

Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?

Citigroup analyst David Lebovitz maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $338 to $351.

Citigroup Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $351

Financial giants have made a conspicuous bullish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) revealed 8 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 12% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $184,200, and 5 were calls, valued at $169,689.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $210.0 to $340.0 for Alnylam Pharmaceuticals during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Alnylam Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Alnylam Pharmaceuticals's whale activity within a strike price range from $210.0 to $340.0 in the last 30 days. 
<h3>Alnylam Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742580956_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$6.9</td>
<td>$6.3</td>
<td>$6.3</td>
<td>$270.00</td>
<td>$63.0K</td>
<td align="right">2</td>
<td align="right">114</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.2</td>
<td>$5.6</td>
<td>$6.1</td>
<td>$260.00</td>
<td>$61.0K</td>
<td align="right">0</td>
<td align="right">100</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.2</td>
<td>$5.6</td>
<td>$6.0</td>
<td>$260.00</td>
<td>$60.2K</td>
<td align="right">0</td>
<td align="right">200</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$25.0</td>
<td>$22.3</td>
<td>$25.0</td>
<td>$250.00</td>
<td>$50.0K</td>
<td align="right">213</td>
<td align="right">10</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$6.5</td>
<td>$3.3</td>
<td>$4.67</td>
<td>$280.00</td>
<td>$37.8K</td>
<td align="right">516</td>
<td align="right">154</td>
</tr>
</tbody>
</table>

<h3>About Alnylam Pharmaceuticals</h3>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
After a thorough review of the options trading surrounding Alnylam Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Alnylam Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>With a volume of 2,074,477, the price of ALNY is up 11.54% at $282.8. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
<h3>Expert Opinions on Alnylam Pharmaceuticals</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $328.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Scotiabank persists with their Sector Outperform rating on Alnylam Pharmaceuticals, maintaining a target price of $338. 
&#x2A; An analyst from Canaccord Genuity has decided to maintain their Buy rating on Alnylam Pharmaceuticals, which currently sits at a price target of $390. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Alnylam Pharmaceuticals, targeting a price of $325. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $310. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Alnylam Pharmaceuticals, targeting a price of $280. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Alnylam Pharmaceuticals with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Check Out What Whales Are Doing With ALNY

Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $385 to $390.

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $390

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $310 to $330.

RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $330

Scotiabank analyst Greg Harrison maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Sector Outperform and raises the price target from $300 to $338.

Scotiabank Maintains Sector Outperform on Alnylam Pharmaceuticals, Raises Price Target to $338

The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) supplemental application for Amvuttra (vutrisiran) in adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM, to reduce cardiovascular mortality, cardiovascular hospitalizations, and <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">urgent heart failure visits</a>.
The approval expands the indication for Amvuttra, which now becomes the first and only therapeutic approved by the FDA for ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44427456/alnylam-announces-fda-approval-of-amvuttra-vutrisiran-the-first-rnai-therapeutic-to-reduce-cardiov" rel="noreferrer noopener">amyloidosis (hATTR-PN) in adults.</a>
ATTR-CM affects approximately 150,000 people in the U.S. and over 300,000 people worldwide.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41169029/alnylams-concedes-its-patent-infringement-case-against-modernas-covid-19-vaccine" rel="noreferrer noopener">Alnylam&#8217;s Concedes Its Patent Infringement Case Against Moderna&#8217;s COVID-19 Vaccine</a>
This approval is based on the HELIOS-B Phase 3 clinical trial. The trial achieved statistical significance compared to placebo on all 10 pre-specified primary and secondary endpoints.
In the overall population, Amvuttra reduced the risk of all-cause mortality and recurrent cardiovascular (CV) events by 28% during the double-blind treatment period of up to 36 months.
Mortality in this population was significantly reduced by 36% through 42 months in a pre-specified secondary endpoint analysis.
In the monotherapy population, Amvuttra reduced the risk of ACM and recurrent CV events by 33% and the risk of mortality by 35% through 42 months.
Amvuttra in hATTR-PN is covered by insurers for around 99% of patients, with the majority paying nothing out-of-pocket. Similar broad coverage and out-of-pocket costs are expected in ATTR-CM, given comparable payer dynamics and the clinical value demonstrated in the HELIOS-B clinical trial.
Marketing authorization applications based on HELIOS-B data are currently under review by several global health agencies including the European Medicines Agency, the Brazilian Health Regulatory Agency, and the Japanese Pharmaceuticals and Medical Devices Agency.
Alnylam remains on track to proceed with additional global regulatory submissions for vutrisiran in 2025.
In 2024, Amvuttra sales reached $970.45 million, up from <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43690782/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlights" rel="noreferrer noopener">$557.84 million a year ago</a>.
Price Action: ALNY stock is up 8.46% at $274.98 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44434720/defense-secretary-slashes-580-million-in-wasteful-spending-targets-overdue-overpriced-projects" target="_blank" rel="noreferrer noopener">Defense Secretary Slashes $580 Million In Wasteful Spending—Targets Overdue, Overpriced Projects</a></li>
</ul>
Image via Shutterstock

Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps

Press Releases

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

COEP

REGN

RPRX

VRTX

AbbVie

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

HC Wainwright & Co.

Scotiabank

Redburn Atlantic

Stifel

JP Morgan

지난주에 가장 성과가 좋았던 대형주 10종목은 다음과 같다.
<ol>
<li>앨나일람 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>): 주가가 17.20% 상승했다. 이는 회사가 RNAi 치료제인 AMVUTTRA에 대한 sNDA를 FDA로부터 승인받았기 때문이다. 이 치료제는 성인 ATTR-CM 치료제이다.<a href="https://www.benzinga.com//node/44436749" target="_blank" rel="noreferrer noopener">자세한 내용은 여기에서 확인해 보자.</a></li>
<li>로쿠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 주가가 15.51% 급등했다. 트럼프 미디어 앤 테크놀로지 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)이 트루스 플러스(Truth+) <a href="https://www.benzinga.com//node/44405898" target="_blank" rel="noreferrer noopener">스트리밍 앱을 로쿠 플랫폼에 출시했다는 발표</a> 이후 상승했다.</li>
<li>로빈후드 마켓츠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 주가가 13.05% 상승했다. 이는 컴퍼스 포인트가 주식을 매수 등급으로 커버리지를 시작하고 <a href="https://www.benzinga.com/quote/hood/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 61달러로 발표한 후</a> 나타났다.</li>
<li>엘빗 시스템즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>): 주가가 11.72% 상승했다. 이는 회사가 2024년 4분기 실적이 예상보다 좋았고 <a href="https://www.benzinga.com//node/44376371" target="_blank" rel="noreferrer noopener">분기 배당금을 주당 0.60달러로 인상</a>했다고 발표한 후 나타났다.</li>
<li>보잉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): 주가가 10.07% 상승했다. 트럼프 대통령이 보잉과 차세대 전투기 계약을 한다고 발표했기 때문이다.</li>
<li>앵글로골드 아샨티 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>): 주가가 10.05% 상승했다. 이는 금과 은의 가격 상승 때문으로 보이며, 금 가격이 사상 최고가를 기록했다.</li>
<li>쇼피파이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 주가가 9.87% 상승했다. 이는 연방준비제도가 <a href="https://www.benzinga.com//node/44406912" target="_blank" rel="noreferrer noopener">금리 동결을 결정한 후</a> 전반적인 시장이 강세를 보인 결과로 볼 수 있다.</li>
<li>사우스웨스트항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>): 주가가 9.77% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/44417227" target="_blank" rel="noreferrer noopener">가격 전망을 상향 조정했다.</a></li>
<li>미쓰비시 UFJ 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>):  주가가 9.66% 상승했다. 이는 연준의 금리 유지 결정 후 전반적인 시장 심리와 동조된 결과로 보인다.</li>
<li>듀오링고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>): 주가가 9.09% 상승했다. 시티즌즈 캐피털 마켓츠가 주식 평가 등급을 시장수익률 상회로 상향 조정하고 목표주가를 400달러로 발표한 후 상승했다.</li>
</ol>
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 11개 대형주들은 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 휴마나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)가 별 등급의 2025년 실적 하락과 이것이 <a href="https://www.benzinga.com//node/41140319" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2026년 품질 보너스 지급에 어떤 영향</a>을 미칠지에 대해 투자자들에게 업데이트한 후 주가는 24.89% 하락했다. 몇몇 분석가들은 <a href="https://www.benzinga.com/quote/hum/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측</a>을 낮췄다.
2. 스텔란티스 N.V.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>)의 주가는 크라이슬러 모기업의 미국 판매가 <a href="https://www.benzinga.com//node/41147560" target="_blank" rel="noreferrer noopener">3분기에 20% 급락</a>했다고 발표한 후 17.06% 하락했다. <a href="https://www.benzinga.com//node/41190669" target="_blank" rel="noreferrer noopener">여러</a> 애널리스트들이 <a href="https://www.benzinga.com/quote/stla/analyst-ratings" target="_blank" rel="noreferrer noopener">주식을 하향 조정</a>했다.
3. 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 10.63% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/41171878" target="_blank" rel="noreferrer noopener">MICA 유럽 규정을 충족하지 않는</a> 스테이블코인에 대한 서비스를 제한할 것이라고 발표했다.
4. 모빌아이 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>)의 주식은 10.15% 하락했다.
5. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)는 <a href="https://www.benzinga.com//node/41182921" target="_blank" rel="noreferrer noopener">R1 및 RCV 플랫폼의 공유 부품</a> 공급 부족으로 인해 회사가 연간 생산 지침을 낮춘 후 지난 주 주가는 10% 하락했다.
6. 퍼스트 솔라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLSR#NASDAQ">FLSR</a>)의 주식은 9.63% 하락했다.
7. 콘아그라 브랜즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)의 주식은 <a href="https://www.benzinga.com//node/41140181" target="_blank" rel="noreferrer noopener">1분기 재무 실적이 예상보다 저조</a>하게 나타났다고 보고한 후 9.12% 하락했다.
8. 플로어 &amp; 데코 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>)의 주식은 8.81% 하락했다.
9. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주가는 8.59% 급락했다. 이 회사는 <a href="https://www.benzinga.com//node/41174110" target="_blank" rel="noreferrer noopener">2차 EGFRm 비소세포폐암(NSCLC) 대상 HARMONi 임상 3상 시험의 등록 완료</a>되었다고 발표했다.
10. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주가는 8.44% 하락했다. 이 회사는 앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)와 진행 중인 특허 침해 소송에서 <a href="https://www.benzinga.com//node/41169029" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">합의에 도달</a>했다.
11. 나이키(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) 주식은 여러 투자 은행들이 <a href="https://www.benzinga.com//node/41147332" target="_blank" rel="noreferrer noopener">1분기 매출 부진에 따라 목표 주가를 하향 조정</a>한 후 8.04% 하락했다.
또한 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A4%91%EA%B5%AD-%EC%A3%BC%EC%8B%9D%EC%9D%B4-%EC%A3%BC%EB%8F%84-%EB%A6%AC-%EC%98%A4%ED%86%A0%EC%99%80-jd%EB%8B%B7%EC%BB%B4%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1/" target="_blank" rel="noopener">미국에 상장된 중국 주식이 또 한 주를 장악 &#8211; 리 오토, JD닷이 지난 주 대형주 상승률 10위 안에 포함되다 (9월 30일~10월 4일): 다른 주식들은 당신의 포트폴리오에 포함되어 있나요?</a></li>
</ul>
사진 출처: rafapress via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)가 예상보다 나은 2분기 재무 결과를 보고하고 <a class="ticker" href="https://www.benzinga.com//node/40085338" target="_blank" rel="noreferrer noopener">트윈스트랜드 바이오사이언스(TwinStrand Biosciences)</a>와 독점 라이센스 계약을 발표한 후 주가는 26.60% 상승했다. 몇몇 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/exas/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측</a>을 하향 조정했다.</li>
<li>앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)가 예상보다 나은 2분기 재무 실적을 발표한 후 주가는 15.35% 상승했다. 애널리스트들은 각자의 <a href="https://www.benzinga.com/quote/alny/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>레즈메드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>)의 주가는 예상보다 나은 4분기 실적을 보고하고 <a href="https://www.benzinga.com//node/40133504" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">분기 배당금을 인상</a>한 후 10.09% 상승했다. 몇몇 분석가들도 주식 가격 예측을 높였다.</li>
<li>코카콜라 콘솔리데이티드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>)의 주가는 회사가 2분기 재무 실적이 <a href="https://www.benzinga.com//node/40081001" target="_blank" rel="noreferrer noopener">전년 대비 증가</a>했다고 보고한 후 12.21% 상승했다.</li>
<li>덱스콤(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)의 주식은 지난주 11.18% 상승하여, 52주 최저점에서 반등했다.</li>
<li>스프라우츠 파머스 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>)의 주가는 회사가 예상보다 나은 2분기 재무 실적을 보고하고 예상치를 웃도는 3분기 실적 가이던스를 발표한 후 11.87% 상승했습니다. 많은 분석가들이 회사의 <a href="https://www.benzinga.com//node/40048771" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가</a>를 높였다.</li>
<li>UL 솔루션즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>)가 <a href="https://www.benzinga.com//node/40063544" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 나은 2분기 재무 실적</a>을 발표한 후 주가는 11.74% 상승했다.</li>
<li>랩코프 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>)의 주가는 예상보다 나은 2분기 재무 실적을 보고하고 FY24 매출 가이던스를 예상치보다 높인 후 11.34% 상승했다. 몇몇 분석가들은 회사에 대한 <a href="https://www.benzinga.com//node/40135030" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 예측</a>을 높였다.</li>
<li>C.H. 로빈슨 월드와이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>)의 주가는 예상보다 나은 2분기 조정 EPS 실적을 발표한 후 10.98% 상승했다. 다수의 기업도 각각의 <a href="https://www.benzinga.com/quote/chrw/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>도어대시(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>)가 <a href="https://www.benzinga.com//node/40116158" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 나은 2분기 매출</a>을 보고한 후 주가는 10.24% 상승했다. 몇몇 분석가들은 주식에 대한 가격 예측을 높였다.</li>
</ol>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%eb%a7%88%ec%9d%b4%ed%81%ac%eb%a1%9c%ec%8a%a4%ed%8a%b8%eb%a0%88%ed%8b%b0%ec%a7%80-%eb%b0%8f-%ec%9d%b8%ed%85%94%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc/" target="_blank" rel="noopener">마이크로스트레티지 및 인텔은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 28일-8월 3일</a><a href="https://www.benzinga.com/news/24/08/40150484/microstrategy-intel-and-moderna-are-among-top-12-large-cap-losers-last-week-july-28-august-3-are-the">)</a></li>
</ul>
사진 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

테마(Tema) ETFs의 설립자이자 CEO인 마우리츠 팟(Maurits Pot)은 비만 치료를 위한 GLP-1 약물 시장은 1조 달러 이상으로 급등할 것으로 예상된다고 <a href="https://www.benzinga.com/exclusives">벤징가(Benzinga)와의 독점 인터뷰</a>에서 그의 낙관적인 예측을 공유했다. 
마우리츠는 &#8220;장기적으로 이것은 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) 사이의 양대 경쟁이 아니라고 생각한다&#8221;고 말하며, 체중 감량 시장에서 널리 퍼져 있는 두개의 기업이 전체 시장을 과점(duopoly)하는 개념에 도전했다.
Pot은 체중 감량 치료제에 대한 수요 증가와 GLP-1 약물의 적용 확대가 이 1조 달러 규모의 시장 기회를 주도할 것이라고 예측한다.
2023년 11월, 테마 ETFs는 체중 감량에 초점을 맞춘 최초의 ETF인 Tema GLP-1, Obesity and Cardiometabolic ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTS#NYSE">HRTS</a>)를 출시했다. SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)에서 추적한 바와 같이, 이 펀드는 개시 이후 25% 상승하여 S&amp;P 500의 성과를 약간 앞섰다.
이 ETF의 주요 보유 종목으로는 일라이 릴리, 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), 노보 노디스크, 앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)가 있으며 각각 약 5~6%의 비중을 갖고 있다. 이 HRTS 포트폴리오는 또한 40개 이상의 기타 체중 감량 관련 회사들로 구성되어 있다.
차트: Tema GLP-1, Obesity and Cardiometabolic ETF는 설정 이후 S&amp;P 500을 능가
<figure class="wp-block-image size-large"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent070524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-422177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-1024x652.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-1024x652.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-300x191.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-768x489.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-1536x978.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10.png 1662w" alt="" width="1024" height="652" /></a></figure>
차트: <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent070524&amp;t=be2bearmibe3na1">벤징가 프로</a> 
<h3 class="wp-block-heading">체중 감량 치료: 응용 분야 및 혁신 확대</h3>
팟(Pot)에 따르면, GLP-1 약물은 곧 체중 감량을 넘어 당뇨병, 심장, 간 및 신장 질환에 적용되고 암, 알츠하이머병, 파킨슨병 및 기타 신경성 질환과 같은 질환을 치료할 수 있는 가능성이 있다고 한다.
기존 주사 방법은 경구 투여 또는 투여 빈도 감소에 초점을 맞춘 새로운 접근법으로 인해 어려움을 겪고 있다. 혁신의 목표는 주 1회 주사에서 잠재적으로 2개월에 한 번으로 전환하는 등 치료법을 덜 침습적으로 만들거나 경구 정제 생산과 같이 제조하기를 훨씬 쉽게 만드는 것이다.
비만은 당뇨병, 심장병, 암 등 다양한 질병을 유발한다. 따라서 비만을 해결하면 여러 가지 건강 문제를 완화하고 GLP-1 약물의 시장 잠재력을 증폭시킬 수 있다.
이 시장은 일라이 릴리 및 노보 노디스크를 넘어 다양한 질병 영역을 다루게 될 것으로 예상된다.
팟은 비만, 당뇨병, 잠재적으로 알츠하이머병이나 암에 대한 용도를 언급하면서 &#8220;세계 인구의 절반이 GLP-1이나 다른 체중 감량 약물을 1차 예방 등의 다른 이유로 복용하는 세상을 볼 수 있다&#8221;라고 말했다.
<h3 class="wp-block-heading">1조 달러 예상의 배경</h3>
전 세계 비만 인구는 2035년까지 10억 명에서 20억 명으로 두 배로 늘어날 것으로 예상된다. 이러한 성장이 없더라도 기존 10억 명의 비만 인구는 상당한 시장을 대표한다.
장기 치료가 현재 비만 인구의 20%에게만 도달한다면, 이는 현재 당뇨병 약물의 보급률과 유사하게 2억 명에 해당한다. 연간 1인당 약가가 12,000달러에서 6,000달러로 인하된다고 가정하면 GLP-1 의약품 시장은 1조 달러를 넘어설 수 있다고 팟이 설명했다.
골드만삭스는 시장 규모를 1,000억~1,300억 달러로 추정하지만 팟은 암, 알츠하이머병, 파킨슨병에 대한 투기적 적용을 고려하기 전에도 시장이 1조 달러에 도달할 수 있다고 믿고 있다. 시장 규모는 지속적으로 과소평가되어 왔으며 추정치는 몇 달마다 증가하고 있다.
특허 만료는 또한 시장을 형성할 것이다. 미국에서는 오젬픽(Ozempic)/위고비(Wegovy)의 특허가 2032년에 만료되고, 유럽에서는 2031년, 중국에서는 2026년에 만료된다.
"특허가 만료되기 전에는 1조 달러 규모의 시장이 될 것이라고 생각한다"라고 팟은 말했다.
<h3 class="wp-block-heading">중소형주에 초점 맞추기</h3>
왜 투자자들이 소수의 대형주 대신 다양한 체중 감량 관련 주식에 집중해야 하는지 묻는 질문에 팟은 일라이 릴리와 같은 대기업들과 달리 &#8220;이 거대한 중소형 생명공학 시장에서 긍정적인 임상 결과의 영향이 훨씬 더 높다&#8221;고 설명했다. 
그는 포트폴리오 균형으로 대형주를 보유하는 것의 중요성을 강조했지만 소규모 회사들이 장기적으로 더 높은 수익을 제공할 수 있다고 지적했다.
팟은 생명공학 부문이 인수합병으로 성숙해 있음을 강조했다. 지난해에만 가치가 10억 달러를 초과하는 생명공학 M&amp;A 거래가 22건 있었다.
머크 앤드 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), 또는 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 같이 비만 사업이 없는 주요 헬스케어 회사들이 인수를 모색할 가능성이 높다.
지금 읽기
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/06/39143220/exclusive-tema-american-reshoring-etf-outshines-s-p-500-without-owning-magnificent-7-stocks-they-can">단독: Tema American Reshoring ETF는 7개 주식을 보유하지 않고도 S&amp;P 500을 능가</a></li>
</ul>
사진: 셔터스톡


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Sector ETFs

Small Cap

Global

Exclusives

Tech

ETFs

ABBV

AMGN

HRTS

단독: GLP-1 체중 감량 약물은 수조 달러 규모의 시장 가능성, 테마 ETFs CEO의 전망

6월은 <a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener" data-google-interstitial="false">섹터 및 산업 성과</a>의 상당한 격차에도 불구하고 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 S&amp;P 500이 3.2% 상승하는 등 주식 시장에서 높은 평가를 받으며 마감되었다.
Technology Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)가 추적하는 기술 부문은 지난달 실적에서 11개 S&amp;P 500 섹터를 주도하며 7.7% 급등해 올해 가장 높은 월간 상승률을 달성했다.
이와는 대조적으로 유틸리티 부문은 Utilities Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)가 6.3% 하락해 2023년 9월 이후 최악의 달을 기록하는 등 부진했다.
<h3 class="wp-block-heading">6월 최고의 성과를 보인 산업 ETF들</h3>
iShares Expanded Tech-Software Sector ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGV#NYSE">IGV</a>)는 지난달 11.3% 상승하여 산업 ETF 중 1위를 차지했다.
이에 뒤이어 VanEck Semiconductor ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>)가 8.4% 상승하며 반도체 부문에서 강력한 모멘텀을 보여주었다.
VanEck Semiconductor ETF는 2023년 10월 최저치를 기록한 이후 무려 87%, 2022년 10월 이후로는 200% 이상 상승해 AI 중심 주식의 눈부신 성장을 반영했다.
월간 실적 측면에서 3위를 차지한 SPDR S&amp;P Biotech ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>)는 4% 상승했다.
소프트웨어 부문에서는 24.9% 상승한 어도비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>), 22.1% 오른 크라우드스트라이크 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), 20% 상승한 오라클(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>)이 눈에 띄는 성과를 거두었다.
브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)는 21% 상승으로 칩 제조업체를 이끌었다. 유니버설 디스플레이 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NYSE">OLED</a>)은 19.7% 증가로 그 뒤를 쫓았고, 코보(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>)는 18% 상승을 기록했다.
생명공학 분야에서 실렉스 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>)는 78.8%의 급등을 경험하여 업계 최고의 상승세를 보였다. 앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)는 63.7% 급등한 반면, 어비디티 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>)는 52%의 강력한 상승세를 보였다.
<h3 class="wp-block-heading">6월 자금 유입량 상위 산업 ETF</h3>
자금 흐름을 조사한 결과 VanEck Semiconductor ETF는 투자자들에게 최고의 선택으로 부상했으며 트레이딩뷰(Tradingview) 데이터에 따르면 10억 달러 이상을 유치하고 9개월 연속 유입을 달성했다. 올해 현재까지 이 펀드는 46억 달러의 순유입을 기록했다.
iShares Expanded Tech-Software Sector ETF는 6월에 약 4억 8천만 달러를 유치하여 6개월 연속 유출을 깨고 2022년 9월 이후 가장 높은 월간 유입을 기록했다. 그러나 연간 순 흐름은 여전히 ​​11억 5천만 달러 마이너스이다.
iShares Biotechnology ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NYSE">IBB</a>)는 투자자들의 높은 관심을 반영하여 지난달 1억 4,800만 달러의 자금을 유입했다. 강력한 유입을 목격한 또 다른 업계는 약 1억 3천만 달러를 유치한 Global X Copper Miners ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COPX#NYSE">COPX</a>)로 대표된다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39577080/manufacturing-contracts-more-than-expected-in-june-putting-pressure-on-profitabilit">6월 제조업 계약 예상보다 많아 &#8216;수익성 압박&#8217;: 수익률 상승, 주식 하락</a></li>
</ul>
사진: 셔터스톡

Broad U.S. Equity ETFs

ADBE

AVGO

COPX

CRWD

OLED

ORCL

QRVO

SCLX

SOXX

6월 상위 성과 업종 ETF: 소프트웨어는 수익을 선도, 칩 메이커들은 가장 많은 자금 유치

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)는 회사가 생산량을 단순화하고 비용을 절감했으며 <a href="https://www.benzinga.com//node/39497161" target="_blank" rel="noreferrer noopener">폭스바겐과의 합작</a> 투자 계획을 발표했다는 보도가 나온 후 지난주 주가가 30.04% 급등했다.</li>
<li>카니발(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUK#NYSE">CUK</a>)의 주식은 <a href="https://www.benzinga.com//node/39481992" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 실적이 예상을 상회하는 결과</a>가 나타나자 17.78% 상승했다.</li>
<li>페덱스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)의 주식은 예상보다 나은 4분기 재무 결과와 지침으로 인해 지난주 17.51% 급등했다. 또한 이 회사는 FY25에 <a href="https://www.benzinga.com//node/39504381" target="_blank" rel="noreferrer noopener">25억 달러</a> 상당의 주식을 다시 매입할 것이라고 발표했다. 몇몇 분석가들은 주식에 대한 <a href="https://www.benzinga.com//node/39509568" target="_blank" rel="noreferrer noopener">목표</a> 가격 예측을 높였다.</li>
<li>삼사라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>)의 주식은 RBC 캐피털(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJ#NYSE">RJ</a>)가 <a href="https://www.benzinga.com/quote/iot/analyst-ratings" target="_blank" rel="noreferrer noopener">47달러의</a> 목표 주가를 유지하고 아웃퍼폼(Outperform) 평가를 재확정함에 따라 16.37% 상승했다.</li>
<li>수자노(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>)의 주식은 인터내셔널 페이퍼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>)의 인수 추진을 <a href="https://www.benzinga.com//node/39519611" target="_blank" rel="noreferrer noopener">중단했다는 소식</a> 이후 12.24% 치솟았다.</li>
<li>카바나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)의 주식은 지난 <a href="https://www.benzinga.com//node/39509401" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">6월 초</a> 윌리엄 블레어(William Blair) 제 44회 연론회에서 자체 운영 계획과 자본 구조에 대한 업데이트 이후 11.93% 상승했다.</li>
<li>FTAI 에비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>)의 주식은 지난주 11.55% 상승했다.</li>
<li>레딧(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NASDAQ">RDDT</a>)의 주식은 <a href="https://www.benzinga.com//node/39494776" target="_blank" rel="noreferrer noopener">자동화된 웹 스크래핑을 차단하기 위한</a> 정책 업데이트를 발표한 후 11.08% 급등했다.</li>
<li>몽고DB(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)의 주식은 지난주 10.57% 상승했다.</li>
<li>앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)의 주식은 회사가 부트리시란(vutrisiran)에 대한 HELIOS-B 3상 연구의 최고 결과를 발표한 후 지속적인 강세가 예상되는 가운데 주가는 10.82% 상승했다. 또한, 다수의 분석가들은 주식에 대한 전망 가격을 <a href="https://www.benzinga.com/quote/alny/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.</li>
</ol>
다음 내용 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/06/39565694/moderna-and-walgreens-boots-alliance-were-among-the-10-biggest-large-cap-losers-last-week-june-23-">모더나와 월그린스 부츠는 지난주 최악의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)</a></li>
</ul>
리비안의 사진

FTAI

MSTR

RDDT

리비안과 카바나는 지난주 최고의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)

월요일 미국 주요 지수들은 혼조세를 보였다. 다우존스 산업평균지수는 0.7% 가까이 오른 39,411.21에 마감했고, S&amp;P 500 지수는 0.3% 하락한 5,447.87에 마감했다. 나스닥 지수는 1.1% 가까이 하락한 17,496.82로 마감했다.
이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:
엔비디(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
엔비디아의 주식은 6.68% 하락하여 118.11달러에 마감했다. 주식의 일일 최고가는 124.46달러, 최저가는 118.04달러이다. 이 주식의 52주 범위는 39.23달러에서 140.76달러 사이에 있다. 이 반도체 회사는 <a href="https://www.benzinga.com/markets/equities/24/06/39462808/semiconductor-nvidia-woes-deepen-nasdaq-100-slips-dow-rallies-bitcoin-sinks-to-60-400-whats-driv">대규모 매도</a> 후 조정 영역에 진입했으며 CEO인 젠슨 황은 1억 달러 이상의 주식을 매도했다.
어펌 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)
어펌의 주식은 12.82% 상승, 33.70달러에 마감했다. 이 주식의 일일 최고가는 34.13달러, 최저가는 30.77달러이다. 이 주식의 52주 범위는 12.81달러에서 52.48달러 사이에 있다. 골드만삭스의 분석가 윌 낸스(Will Nance)가 어펌을 매수 등급과 42달러 목표 가격으로 평가한 후 <a href="https://www.benzinga.com/news/24/06/39464043/whats-going-on-with-affirm-stock">주가가 상승</a>했다.
카니발 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>)
카니발의 주식은 1.99% 상승, 16.39달러에 마감했다. 이 주식의 일일 최고가는 16.5달러, 최저가는 16달러이다. 이 주식의 52주 범위는 10.84달러에서 19.74달러 사이에 있다. 이 회사는 화요일에 <a href="https://www.benzinga.com/general/entertainment/24/06/39464753/carnival-stock-in-strong-bullish-trend-ahead-of-q2-earnings-why-analyst-sees-multiyear-port" target="_blank" rel="noopener" data-google-interstitial="false">2분기 실적</a>을 보고할 예정이며, 월스트리트는 EPS가 마이너스 20센트, 매출이 57억 달러에 이를 것으로 예상하고 있다.
앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)
앨라일의 주식은 34.52% 급등해 222.90달러에 마감했다. 이 주식의 일일 최고가는 231.64달러, 최저가는 209.23달러이다. 이 주식의 52주 범위는 141.98달러에서 231.64달러 사이에 있다. 이 회사가 심근병증을 동반한 ATTR 아밀로이드증(ATTR-CM)에 대해 개발 중인 연구용 RNAi 치료제인 부트리시란(vutrisiran)에 대한 HELIOS-B 3상 연구에서 <a href="https://www.benzinga.com/general/biotech/24/06/39456940/alnylams-closely-watched-phase-3-heart-disease-trial-of-vutrisiran-hits-primary-endpoint-shares-s">긍정적인 결과</a>를 공개한 후 주가가 상승했다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주식은 0.23%의 소폭 하락, 182.58달러에 마감했다. 이 주식의 일일 최고가는 188.8달러, 최저가는 182.55달러이다. 이 주식의 52주 범위는 138.8달러에서 299.29달러 사이에 있다. 게리 블랙(Gary Black)은 테슬라에서 일론 머스크의 560억 달러 급여 패키지에 이의를 제기한 &#8216;토네타 대 머스크(Tornetta vs. Musk)&#8217; 사건에서 델라웨어 판사의 사법 활동주의를 <a href="https://www.benzinga.com/news/24/06/39449373/tesla-bull-gary-black-slams-delaware-chancellors-judicial-activism-in-elon-musks-56b-pay-package-cas" target="_blank" rel="noopener" data-google-interstitial="false">비판</a>하여 사법 역할과 입법 대응에 대한 광범위한 논쟁으로 이어졌다.
Jirapong Manustrong의 셔터스톡에서 사진
Benzinga의 최상의 <a href="Premarket Movers &amp; News">프리마켓 움직임과 뉴스</a>를 준비하십시오
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에서 제작되었습니다. 그리고 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noopener noreferrer">Shivdeep Dhaliwal</a>에 의해 수정되었습니다.

Comments

Alnylam Pharmaceuticals

뉴스

에 대한 최신 뉴스 Alnylam Pharmaceuticals (NASDAQ:ALNY) 주식

일요일, 3월 23, 2025

일요일, 10월 06, 2024

일요일, 8월 04, 2024

일요일, 7월 07, 2024

화요일, 7월 02, 2024

일요일, 6월 30, 2024

화요일, 6월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌